Anticancer Drugs in End‐Stage Kidney Disease Patients

E-ISSN： 1525-139x|28|4|413-416

ISSN： 0894-0959

Source： SEMINARS IN DIALYSIS, Vol.28, Iss.4, 2015-07, pp. : 413-416

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

AbstractThe increased incidence of malignancies in patients with chronic kidney patients and especially in end‐stage kidney disease (ESKD) patients has been discussed since the mid‐1970s. Consequently, oncologists, nephrologists, and pharmacists are increasingly facing challenging situations of cytotoxic drug handling in dialysis patients because of pharmacokinetic modifications. In these patients, two main issues must be considered. First, the absence of renal function in hemodialysis (HD) patients may necessitate drug dosage reduction. Therefore, drug prescription must be cautiously checked before administration with appropriate dosage adjustment whenever necessary to ensure efficacy while avoiding overdosage and related side effects. Second, drug clearance by dialysis session must be taken into account for appropriate chemotherapy timing administration to avoid drug removal, which may result in a loss of efficacy. These two main considerations must not be considered as a contra‐indication to chemotherapy in ESKD patients, but more as a need for an individualized prescription according to available recommendations.